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Abstract: The synthesis of N-acetylneuraminic acid
(Neu5Ac) derivatives is drawing more and more
attention in glycobiology research because of the
important role of sialic acids in e.g. cancer,
bacterial, and healthy cells. Chemical preparation of
these carbohydrates typically relies on multistep
synthetic procedures leading to low overall yields.
Herein we report a continuous flow process involv-
ing N-acetylneuraminate lyase (NAL) immobilized
on Immobead 150P (Immobead-NAL) to prepare
Neu5Ac derivatives. Batch experiments with Immo-
bead-NAL showed equal activity as the native
enzyme. Moreover, by using a fivefold excess of
either N-acetyl-D-mannosamine (ManNAc) or pyr-
uvate the conversion and isolated yield of Neu5Ac
were significantly improved. To further increase the
efficiency of the process, a flow setup was designed
providing a chemoenzymatic entry into a series of
N-functionalized Neu5Ac derivatives in conversions
of 48–82%, and showing excellent stability over 1
week of continuous use.
Keywords: N-acetylneuraminic acid; N-acetylneura-
minate lyase; flow chemistry; enzyme immobilization
Carbohydrates constitute an important class of bio-
molecules with a wide array of biological functions
due to the complexity of individual saccharide moieties
and the numerous branching possibilities.[1] A unique
carbohydrate that is generally encountered at the outer
surface of glycans is the sialic acid N-acetylneuraminic
acid (Neu5Ac, 1). Neu5Ac has over 50 structurally
related analogues, which can be recognized by specific
receptors.[2] These receptors play a central role in
health and disease and are potential targets for
neuraminic acid-based drugs.[3]
Neu5Ac derivatives are most often prepared using
multistep organic synthesis which is laborious, ex-
pensive, time consuming and typically low yielding.
Alternatively, Neu5Ac derivatives can be obtained by
using N-acetylneuraminate lyase (NAL), an enzyme
which catalyzes the reversible aldol reaction of
Neu5Ac (1) to form N-acetyl-D-mannosamine (2,
ManNAc) and pyruvate (3, Scheme 1).[4] It has been
shown that by using an excess of pyruvate or ManNAc
derivative, the equilibrium is shifted toward the
Scheme 1. The reversible aldol reaction of Neu5Ac (1) to
ManNAc (2) and pyruvate (3) catalyzed by NAL.
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Neu5Ac product.[5] In contrast to chemically derived
Neu5Ac substrates, ManNAc derivatives are syntheti-
cally readily accessible and due to the promiscuity of
NAL give straightforward access to Neu5Ac deriva-
tives.
The immobilization of NAL has been reported by
several research groups and shows promise for large
scale Neu5Ac production.[6] More recently, also cross-
linked examples have been reported including CLEA,
CLEC and CLIB which are notably stable, but
challenging to prepare.[7] To the best of our knowledge,
immobilized NAL has never been used in a continuous
flow setup for the preparation of synthetic Neu5Ac
derivatives. Based on the broad experience with
chemoenzymatic reactions in our group, both in batch[8]
and in flow systems,[9] and on our expertise in the
chemistry and biology of sialic acids,[2,10] we herewith
report a straightforward continuous flow system con-
taining immobilized NAL providing a new and
efficient chemoenzymatic entry into biologically rele-
vant N-functionalized Neu5Ac derivatives.
First, we investigated the immobilization of NAL to
increase stability, shelf life, and ease of application in
flow chemistry. Our initial attempt using an aqueous
NAL solution in combination with oxirane-functional-
ized Immobead 150P (corresponding to 62 mg NAL
per g Immobead 150P) was successful providing
immobilized NAL (Immobead-NAL) with immobiliza-
tion efficiencies of up to 74% (see: Supporting
Information 1).[11]
In order to test the activity of Immobead-NAL, the
chemoenzymatic synthesis of Neu5Ac (1) was inves-
tigated in batch experiments using ManNAc (2),
pyruvate (3) and native NAL in a homogeneous
solution and Immobead-NAL in a heterogeneous
formulation. In literature most often an excess of
pyruvate is used, but this requires tedious purification
in which residual buffer salts and pyruvate have to be
removed.[3d,5d,12] In contrast, we showed that a fivefold
molar excess of ManNAc in H2O led to conversions of
up to 77% (Table 1), while the excess of ManNAc
could be easily removed by anion exchange. All
Immobead-NAL formulations were shown to be
effective in the preparation of Neu5Ac with compara-
ble conversions. Interestingly, three months old Immo-
bead-NAL (stored at 0 °C) showed only a slight
decrease in activity, indicating that the immobilized N-
acetylneuraminate lyase can be stored for an extended
period of time. Finally, increasing the molar excess of
ManNAc did not lead to higher conversions and
isolated yields, therefore a molar ratio of 5 of ManNAc
and pyruvate was considered optimal in this setup.
We then applied Immobead-NAL in a flow system
to efficiently screen reaction parameters and optimize
conversions (Table 2). A flow reactor was designed
using an HPLC cartridge, filled with freshly prepared
Immobead-NAL, as a packed-bed reactor (see: Sup-
porting Information 3). Prior to administering the
substrates to the packed-bed reactor, it was preheated
to 38 °C using a water bath. Perfluoroalkoxy (PFA)
tubing (OD 1/16”, ID 1/50”) and flangeless fittings (1/
16”) were used to connect the linear flow setup.
Table 1. The synthesis of Neu5Ac (1) in batch with various
Immobead-NAL formulations and amounts of pyruvate.[a]
NAL formulation ManNAc
[mM]
pyruvate
[mM]
conversion
(%)[b]
aqueous
NAL
250 50
25
12.5
67
59
60
crystalline
NAL
250 50
25
12.5
77
79
74
Immobead-NAL
(1 month)
250 50
25
12.5
62
65
63
Immobead-NAL
(3 months)
250 50
25
12.5
58
57
63
[a] Conditions: ManNAc (2, 450 μmol) and sodium pyruvate (90
or 45 or 23 μmol) in H2O (1.8 mL) at 38 °C for 24 h.
[b] Determined by 1H-NMR analysis of the crude reaction
mixture.
Table 2. The effect of stoichiometry and concentration on the
preparation of Neu5Ac (1) using Immobead-NAL in a continu-
ous flow system.[a]
entry pyruvate
[mM]
ManNAc
[mM]
conversion
(%)[b]
1 1000 100 52
2 500 100 36
3 300 100 19
4 100 100 15
5 33 100 19
6 20 100 40
7 10 100 41
8 50 250 71
9 80 400 76
10 100 500 82
[a] Conditions: The solution (900 μL) was injected in a sample
loop (1 mL) and pumped (0.05 mL ·min  1) over the Im-
mobead-NAL column at 38 °C and collected for 1.5 h.
[b] Determined by 1H-NMR analysis of the crude reaction
mixture.
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Initially we investigated stoichiometry and concen-
tration as process parameters in the synthesis of
Neu5Ac (1) in flow. At a fixed concentration of
100 mM ManNAc, neither excess of pyruvate nor
ManNAc led to increase of the conversion beyond
50% (Table 2, entries 1–7). Attempts at lower flow
speed did also not improve the conversion when using
a fivefold excess of ManNAc (2) with respect to
pyruvate (3, see: Supporting Information 2). Interest-
ingly, use of higher concentrations of ManNAc (2) led
to higher conversions of up to 82% (Table 2, entries 8–
10). This result is supported by mechanistic insights of
Wong et al.[4a] and by Groher and Hoelsch[13] showing a
correlation in increased substrate concentration and its
positive influence on Neu5Ac production. The upper
limit for ManNAc concentrations was set to 500 mM
due to its solubility in aqueous medium.
To broaden the scope of the chemoenzymatic
process, synthetic ManNAc derivatives 4–10 were
prepared in batch and subjected to the flow conditions
(Scheme 2, see also: Supporting Information). In this
reaction, the NAL appeared sufficiently promiscuous
to successfully convert all synthetic ManNAc deriva-
tives into the corresponding Neu5Ac analogues 11–17.
Thus, the enzyme shows a relatively large substrate
scope, which is not too much influenced by the fact
that the water solubility of the ManNAc derivatives
decreases with increasing size of the protecting group.
In addition to monitoring conversions, the sialic acid
products 11–17 were also obtained in fairly reasonable
isolated yields confirming the synthetic feasibility of
this system (Scheme 2). This includes the propargylox-
ycarbonyl (Poc)-functionalized Neu5Ac derivative 16
which has been extensively used in our group and was
shown to be an effective substrate in bioorthogonal
glycobiology research.[2b,10]
Finally, we were interested in the robustness of the
system and studied a seven-day continuous flow
experiment. By pumping a stock solution of ManNAc
(2, 55.7 g, 500 mM) and pyruvate (3, 5.5 g, 100 mM)
over the Immobead-NAL reactor (approximately
35 mg NAL), more than 10 g of Neu5Ac (1) was
produced. Even after 168 hours of continuous pumping
at 0.05 mL ·min  1 marginal decrease in enzyme activ-
ity was observed (Figure 1, see also: Supporting
Scheme 2. The use of ManNAc derivatives 4–10 in the synthesis of Neu5Ac derivatives 11–17.
Figure 1. Preparative scale formation of Neu5Ac (1) in a
continuous flow setup. Conditions: ManNAc (2, 500 mM),
pyruvate (3, 100 mM), H2O, Immobead-NAL, flow
0.05 mL ·min  1, 38 °C.
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Information 4). The crude mixture was purified using
anion exchange chromatography resulting in effective
recovery of ManNAc (2) and production of Neu5Ac
acid (1) in 58% isolated yield between time interval 0–
120 h. These results clearly underline the stability of
Immobead-NAL and the feasibility to scale up the
flow process.
In summary, N-acetylneuraminate lyase (NAL) was
immobilized and used to optimize the conversion of
ManNAc and pyruvate into Neu5Ac. The oxirane-
containing resin Immobead 150P was coupled to NAL
with a binding efficiency of up to 74%. The resulting
Immobead-NAL showed to be stable in aqueous
solution over at least three months of storage. Optimal
conversions were obtained using 500 mM ManNAc,
100 mM pyruvate and a flow rate of 0.05 mL ·min  1,
giving conversions of up to 82%.
We also demonstrated that the system was effective
in the synthesis of a library of differently N-substituted
Neu5Ac derivatives. Finally, the reactor was subjected
to a durability test of 168 hours showing a relatively
small decrease of N-acetylneuraminate lyase activity
over a week time. Thus, using this immobilized lyase,
an efficient and stable continuous flow process has
been developed for the preparation of neuraminic acid
derivatives.
Experimental Section
Chemicals and Enzymes
Chemicals used in this study were purchased from Fluorochem,
Sigma Aldrich and Carbosynth with a purity grade of �95%.
Demineralized water was used during all experiments. N-
Acetylneuraminate lyase (NAL) was used as a crystalline
powder (8.7 U ·mg  1) or a suspension in aqueous solution
(111 U ·mL  1). The crystalline powder and aqueous solution
were kept cool at 4 °C, and the latter was shaken before use.
Immobilization of NAL
The immobilization procedure comprised incubation of Immo-
bead-150P (300 mg) and N-acetylneuraminate lyase (crystalline:
50 mg, 8 U mg  1 or solution: 900 μL, 111 U ·mL  1) dissolved in
aqueous K2PO4 (1.25 M, pH=8.0, 45 mL) in a falcon tube. The
mixture was shaken for 24 h at 20 °C, and thereafter filtered
using a cellulose paper. The obtained grain was washed twice
with demineralized water (45 mL), and collected again. The
beads were diluted in a glycine solution (2.0 M, pH=8.5,
45 mL) and shaken for 24 h at 20 °C, and thereafter filtered
using cellulose paper. The Immobead-150P was washed twice
with demineralized water (30 mL), and twice with aqueous
K2PO4 (0.1 M, pH=7.4, 30 mL). The obtained immobilized
lyase was stored at 4 °C in a falcon tube, and used within three
months of preparation.
Determination of Binding Efficiency Using Lowry’s
Protein Determination
The binding of N-acetylneuraminate lyase to the beads was
determined via the Lowry’s protein assay of the washings
during enzyme immobilization and measured in triplo.[11] The
concentration of free protein was determined, effectively
providing information about the total amount of protein coupled
to the beads. The standard curve for protein determination was
conducted using solutions of 0.02 mg ·mL  1 to 0.1 mg ·mL  1 of
Bovine Serum Albumin (BSA) purchased from Sigma-Aldrich.
Hereafter the protein concentration of aqueous N-acetylneur-
aminate lyase (100 μL) was determined in triplo, and used to
determine the protein content of the immobilization washings.
Anion Exchange Purification of Neu5Ac (1)
A short cylindrical column (�5×1.5 cm; h×d) was charged
with DEAE-Sephadex A-25 Cl  (�4.5 g) and swollen using
aqueous NH4HCO3 (1.5 M, 15 mL). The resin was filtered and
washed thrice with water (3×15 mL) before addition of the
reaction mixture. The crude mixture was added to the resin and
washed with water, followed by an increasing v/v% of formic
acid in water, up to 20%. The obtained products were
concentrated in vacuo.
Flow Chemistry Setup
The Immobead-NAL resin (700 mg) was loaded directly in an
HPLC cartridge (�1.5 mL) using vacuum suction followed by
washing with copious amounts of demineralized water. The
ManNAc/pyruvate solution was prepared in demineralized
water, and the pH adjusted to 7.0–7.5 using 1 M aqueous NaOH
or HCl and a digital pH indicator. The HPLC cartridge was
connected to the HPLC pump, and heated to 38 °C in a water
bath. After 30 min at 38 °C, the pump was started at
0.05 mL ·min  1. After the reaction mixture was pumped, addi-
tional demineralized water (�5 mL) was used to remove
remaining reactants. The product was concentrated in vacuo and
the conversion determined using 1H-NMR in D2O.
Preparative Scale Experiment
The Immobead-NAL resin (700 mg) was loaded directly in an
HPLC cartridge (�1.5 mL) using vacuum suction followed by
washing with copious amounts of demineralized water. Man-
NAc (55.7 g, 252 mmol) and sodium pyruvate (5.55 g,
50.4 mmol) were added to water (504 mL) and the pH was
adjusted to 7.0–7.5 using 1 M aqueous NaOH or HCl using a
digital pH indicator. The HPLC cartridge was connected
directly to the HPLC pump without the sample loop, and heated
to 38 °C in a water bath. After 30 min at 38 °C, the pump was
set to 0.05 mL ·min  1. After the indicated time intervals, the
reaction mixture was separately collected for 10 min (3×). The
samples were concentrated in vacuo and the conversion
determined using 1H-NMR in D2O.
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